title: Non-cardiac chest pain: prevalence of reflux disease and response to acid suppression in an Asian population.
abstract: BACKGROUND
  Gastroesophageal reflux disease is thought to be the commonest cause of 'non-cardiac chest pain'. The use of proton-pump inhibitors resulting in improvement in the chest pain symptom would support this causal association.
  
  
  OBJECTIVE
  To determine the prevalence of gastroesophageal reflux disease in non-cardiac chest pain and the response of chest pain to proton-pump inhibitor therapy.
  
  
  METHODS
  Patients with recurrent angina-like chest pain and normal coronary angiogram were recruited. The frequency and severity of chest pain were recorded. All patients underwent esophagogastroduodenoscopy and 48-h Bravo ambulatory pH monitoring before receiving rabeprazole 20 mg bd for 2 weeks.
  
  
  RESULTS
  The prevalence of gastroesophageal reflux disease was 66.7% (18/27). The improvement in chest pain score was significantly higher in reflux compared to non-reflux patients (P = 0.006). The proportion of patients with complete or marked/moderate improvement in chest pain symptoms were significantly higher in patients with reflux (15/18, 83.3%) compared to those without (1/9, 11.1%) (P < 0.001).
  
  
  CONCLUSIONS
  The prevalence of gastroesophageal reflux disease in patients with 'non-cardiac chest pain' was high. The response to treatment with proton-pump inhibitors in patients with reflux disease, but not in those without, underlined the critical role of acid reflux in a subset of patients with 'non-cardiac chest pain'.
authors.affiliation: Divisions of Gastroenterology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
authors.forename: Hanizam
authors.initials: H
authors.lastname: Mohd
authors.forename: Choon-Seng
authors.initials: CS
authors.lastname: Qua
authors.forename: Choon-Heng
authors.initials: CH
authors.lastname: Wong
authors.forename: Wan
authors.initials: W
authors.lastname: Azman
authors.forename: Khean-Lee
authors.initials: KL
authors.lastname: Goh
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D044466:Asian People / Q000706:statistics & numerical data*; D002637:Chest Pain / Q000208:ethnology* / Q000209:etiology / Q000517:prevention & control*; D016145:Endoscopy, Digestive System; D050782:Esophageal pH Monitoring; D005260:Female; D005764:Gastroesophageal Reflux / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000208:ethnology*; D006801:Humans; D008296:Malaysia / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011446:Prospective Studies; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D064750:Rabeprazole; D012008:Recurrence; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D054328:Proton Pump Inhibitors; D064750:Rabeprazole